The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries

Autor: Gernot Fugger, Lucie Bartova, Chiara Fabbri, Giuseppe Fanelli, Markus Dold, Marleen Margret Mignon Swoboda, Alexander Kautzky, Joseph Zohar, Daniel Souery, Julien Mendlewicz, Stuart Montgomery, Dan Rujescu, Alessandro Serretti, Siegfried Kasper

Publikováno v: European Archives of Psychiatry and Clinical Neuroscience. 272:715-727

Introduction Due to favorable antidepressant (AD) efficacy and tolerability, selective-serotonin reuptake inhibitors (SSRIs) are consistently recommended as substances of first choice for the treatment of major depressive disorder (MDD) in internatio

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16a1fb7a59951bb1778868c3996c1a34
https://doi.org/10.1007/s00406-021-01368-3

Efficacy of Fluoxetine, Riluzole and Amiloride in treating neuropathic pain associated with secondary progressive multiple sclerosis. Pre-specified analysis of the MS-SMART double-blind randomised placebo-controlled trial

Autor: Peter Foley, Richard A Parker, Floriana de Angelis, Peter Connick, Siddharthan Chandran, Carolyn Young, Christopher J Weir, Jeremy Chataway

Publikováno v: Foley, P, Parker, R A, De Angelis, F, Connick, P, Chandran, S, Young, C, Weir, C J & Chataway, J 2022, ' Efficacy of Fluoxetine, Riluzole and Amiloride in treating neuropathic pain associated with secondary progressive multiple sclerosis. Pre-specified analysis of the MS-SMART double-blind randomised placebo-controlled trial ', Multiple Sclerosis and Related Disorders, vol. 63, 103925 . https://doi.org/10.1016/j.msard.2022.103925

BackgroundEvidence-based treatment of pain in people with MS presents a major unmet need.ObjectiveWe aimed to establish if use of Fluoxetine, Riluzole or Amiloride improved neuropathic pain outcomes in comparison to placebo, in adults with secondary

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::042dc5e11f1282aae6776482432792b5
https://doi.org/10.1016/j.msard.2022.103925

Investigating an in silico approach for prioritizing antidepressant drug prescription based on drug-induced expression profiles and predicted gene expression

Autor: Cathryn M. Lewis, Alessandra Minelli, Chiara Fabbri, Massimo Gennarelli, Chiara Magri, Edoardo Giacopuzzi, Oliver Pain, Muhammad Shoaib

Publikováno v: The pharmacogenomics journal. 21(1)

In clinical practice, an antidepressant prescription is a trial and error approach, which is time consuming and discomforting for patients. This study investigated an in silico approach for ranking antidepressants based on their hypothetical likeliho

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd90524488f69675e71b838a7e24bc56
https://pubmed.ncbi.nlm.nih.gov/32943772

Benzodiazepines as a Monotherapy in Depressive Disorders: A Systematic Review

Autor: Karl Rickels, Richard Balon, Jenny Guidi, Giada Benasi, Emanuela Offidani, Giovanni A. Fava

Publikováno v: Psychotherapy and Psychosomatics. 87:65-74

Background: The aim of this paper was to perform a systematic review and, when feasible, a meta-analysis of randomized controlled trials (RCT) which used benzodiazepines (BZD) as a monotherapy versus placebo, antidepressant drugs (AD), or both. Metho

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06002f85ed8ec74de0c0a71697349919
https://doi.org/10.1159/000486696

Systems Approach to Identify Common Genes and Pathways Associated with Response to Selective Serotonin Reuptake Inhibitors and Major Depression Risk

Autor: Priyanka Singh, Mamta Sood, Debleena Guin, Harpreet Kaur, Luciano Saso, Neha Kanojia, Ankit Srivastava, Ritushree Kukreti, Jyoti Yadav, Divya Vohora, Hitesh Gupta, Rakesh K Chadda

Publikováno v: International Journal of Molecular Sciences
Volume 20
Issue 8
International Journal of Molecular Sciences, Vol 20, Iss 8, p 1993 (2019)

Despite numerous studies on major depressive disorder (MDD) susceptibility, the precise underlying molecular mechanism has not been elucidated which restricts the development of etiology-based disease-modifying drug. Major depressive disorder treatme

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b56c2bc4f732c452a3caafbd89223da7